$14.67−0.81 (−5.23%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$14.99+0.32 (+2.18%)
After hours: Nov 16, 2026, 4:14 PM ET
Nurix Therapeutics (NRIX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~29.6%/yr (FY21→FY25), net margin −314.9%. Worth your attention in FY25: Share count (+102.0%) and Capex step-up ($14.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲54.0%
84.0
FY21→FY25CAGR +29.6%/yr
Net income ($M)▼36.6%
−264.5
FY21→FY25CAGR —
Free cash flow ($M)▼44.9%
−263.5
capex stepped upCAGR —
Diluted EPS▼5.9%
−3.05
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+102.0%
42.9mn → 86.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$14.0M
▲51% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-315¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -314.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7461, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 701,936.0 | 83,980.0 | 54,549.0 | 76,987.0 | 38,627.0 | 29,750.0 | ▲54.0% | +29.6% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 701,936.0 | 83,980.0 | 54,549.0 | 76,987.0 | 38,627.0 | 29,750.0 | ▲54.0% | +29.6% |
Research & development | 334,074.0 | 316,903.0 | 221,632.0 | 189,148.0 | 184,497.0 | 116,434.0 | ▲43.0% | +28.4% |
Selling, general & admin | 78,205.0 | 52,743.0 | 45,944.0 | 42,902.0 | 37,997.0 | 31,202.0 | ▲14.8% | +14.0% |
Total operating expenses | 412,279.0 | 369,646.0 | 267,576.0 | 232,050.0 | 222,494.0 | 147,636.0 | ▲38.1% | +25.8% |
Operating incomefeeds ROC rank | 289,657.0 | −285,666.0 | −213,027.0 | −155,063.0 | −183,867.0 | −117,886.0 | ▼34.1% | — |
Other income, net | 18,555.0 | 21,969.0 | 19,728.0 | 11,115.0 | 3,507.0 | 823.0 | — | — |
Pretax income | 308,212.0 | −263,697.0 | −193,299.0 | −143,948.0 | −180,360.0 | −117,063.0 | ▼36.4% | — |
Income tax | — | 760.0 | 270.0 | 0.0 | 0.0 | 131.0 | ▲181.5% | +55.2% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 294,877.0 | −264,457.0 | −193,569.0 | −143,948.0 | −180,360.0 | −117,194.0 | ▼36.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.30 | −3.05 | −2.88 | −2.65 | −3.71 | −2.73 | ▼5.9% | — |
Diluted shares (mn) | 116.15 | 86.67 | 67.12 | 54.34 | 48.61 | 42.90 | ▲29.1% | +19.2% |
| Margins | ||||||||
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | 41.3% | −340.2% | −390.5% | −201.4% | −476.0% | −396.3% | ▲50.4pp | +56.1pp |
Net margin98th pct in Healthcare | 42.0% | −314.9% | −354.9% | −187.0% | −466.9% | −393.9% | ▲39.9pp | +79.0pp |
† TTM = trailing four quarters through 2026-08-31.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-01-28 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Nurix Therapeutics' revenue last fiscal year?
Nurix Therapeutics reported revenue of $84.0M in fiscal 2025, up 54.0% from fiscal 2024.
What was Nurix Therapeutics' net income?
Nurix Therapeutics reported net income of −$264.5M in fiscal 2025, a net margin of −314.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

